evaluation of tmb in keynote-189: pembrolizumab ct vs placebo ct for nonsquamous nsclc
Published 5 years ago • 152 plays • Length 10:32Download video MP4
Download video MP3
Similar videos
-
2:02
keynote-189: chemo plus pembrolizumab for nsclc
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
10:32
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
0:59
dr. rodriguez-abreu on updated results from the keynote-189 trial in nsclc
-
4:53
chemo-immunotherapy in nsclc: the keynote-189 trial
-
3:29
brilliant advent fs 9 | surgical microscope | better focus & perspective | appasamy associates
-
9:32
how to use 9d bioplasm body health analyzer
-
34:38
pim course: lecture 10: benchmarking and workload suitability on pim - fall 2022
-
1:55
dr. kim on the keynote-189 trial in metastatic nsclc
-
7:29
first-line treatment recommendations based on tmb
-
6:32
keynote-189: clinical implications in patients with less than 1% tumor pd-l1 expression (bmic-033)
-
7:58
keynote-189: clinical implications for high tumor pd-l1 expression (bmic-031)
-
1:08
dr. stinchcombe on the keynote-189 trial in lung cancer
-
5:33
significance of keynote-189 in nsclc
-
6:16
keynote-189: clinical implications in patients with low (1-49%) tumor pd-l1 expression (bmic-032)
-
3:03
keynote-189 update: 4-year follow-up of fl pembro chemo metastatic nsclc
-
8:19
keynote trial data: pembrolizumab’s role in nsclc
-
13:03
early tnbc - pembrolizumab chemotherapy: pathologic complete response in key subgroups
-
4:52
researcher comment: final analysis of keynote-189 | delvys rodriguez-abreu